DOXORUBICIN NAPROD

DOXORUBICINE

Public price

91,50 MAD

Active substance

DOXORUBICINE

Laboratory

NOVOPHARMA

Reimbursable

What is this medicine?

An anthracycline topoisomerase inhibitor that exerts cytotoxic effects on malignant cells by inhibiting nucleotide replication and the action of DNA and RNA polymerases, and by forming DNA-cleavable complexes with topoisomerase II.

Verified summary

DOXORUBICINE, POUDRE POUR SOLUTION INJECTABLE EN FLACON A RECONSTITUER PAR 5 ML DE SOLUTION, 10 MG, BOITE DE 1

Common uses

Treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma, and as a component of multi-agent adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer.

Class

anthracycline topoisomerase inhibitor

Laboratory

NOVOPHARMA

Availability note

Reimbursable

Hospital price

57,20 MAD

Strength

10 MG

Form

POUDRE POUR SOLUTION INJECTABLE EN FLACON A RECONSTITUER PAR 5 ML DE SOLUTION

Presentation

BOITE DE 1

Commercial status

Commercialisé AO

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-06-01: 91,50 MAD

Available presentations and strengths